Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
FHAD1 antisense RNA 1 (FHAD1-AS1) is a long non-coding RNA (lncRNA) that is transcribed antisense to the coding gene FHAD1 (forkhead-associated phosphopeptide binding domain 1). There is currently no substantive publicly available information detailing its established biological function, roles in disease, druggability, or any recognized role as a receptor, enzyme, transporter, or therapeutic target.\n\nThe submitted target "FHAD1 antisense RNA 1 (FHAD1-AS1)" does not match any established therapeutic target class, such as receptor, transporter, or enzyme, nor does it correspond to any major drug target. Available literature and curated gene/protein databases focus on *FHAD1*, a protein-coding gene with a forkhead-associated domain, but not on the antisense RNA (FHAD1-AS1). There is no evidence that FHAD1-AS1 (the antisense lncRNA) is a therapeutic target, biomarker, or implicated directly in any disease, nor is it discussed as a molecule interacting with drugs in the provided or canonical sources. Most available data pertains to the coding gene FHAD1, not its antisense RNA, indicating that FHAD1-AS1 may be either rarely studied or possibly misidentified as a target.\n\nIn summary, FHAD1 antisense RNA 1 (FHAD1-AS1) is a putative long non-coding RNA; current evidence does not support its identification as a validated therapeutic target, nor does it have well-documented biological functions or disease associations in the literature. If you are seeking information on the protein-coding FHAD1 gene/protein, detailed and structured data is available; however, that is a distinct entity from "FHAD1 antisense RNA 1" and should not be conflated.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on FHAD1 antisense RNA 1 (FHAD1-AS1).